ClinicalTrials.gg
CompletedNCT03321058Updated Oct 25, 2017

Polymedication-Check With Insight in Patients' Medication Organisation and Comprehension of Generics

An observational study in Medication Therapy Management and Medication Adherence, sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-25.

Sponsored by University Hospital, Basel, Switzerland · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
125
Ages
18 Years and older
Sex
All
01

Study summary

Patients using multiple drugs including generics have found different solutions to manage their medication. During a Polymedication-Check (medication review type 2a service in community pharmacies) additional information about the organisation of patients' medication in daily life will be compiled in Swiss community pharmacies. Data will allow to better address patients' needs in their medication organisation and comprehension of generics.

02

Conditions studied

  • Medication Therapy Management
  • Medication Adherence

Browse trials for

Keywords

  • Drug Substitution
  • Multicompartment Compliance Aid
03

In context

Medication Adherence

937 studies on the registry are indexed under Medication Adherence; 159 are open to participants now.

This study's enrollment of 125 is below the median of 250 across 148 observational studies indexed under Medication Adherence.

Browse Medication Adherence studies →

Lead sponsor

University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population comprises adults (18 years and older) with at least 4 prescribed medicines which they are taking for at least 3 months. One of those medicines must be a generic drug, one must be prescribed for a cardiovascular condition (ATC C01-10). Patients cannot have their medication provided in a Multicompartment Compliance Aid or a similar device by a specific service like home care, pharmacy or home for elderly.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 4 medicines for at least 3 months
  • at least 1 generic drug
  • at least 1 medicine of ATC code cardiovascular system (C01-10)

Exclusion criteria

Exclusion Criteria:

  • medication provided in Multicompartment Compliance Aid or similar device by specific service (pharmacy, elderly home, home care)
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
125 participants (actual)
Patient registry
No

Interventions

  • BehavioralAssessment

    Assessment of patients' medication organisation and comprehension of generics

06

What researchers measure

Primary outcomes

  1. Insight in patients' organisation of polymedication

    Patients organise their multiple medications differently in daily life. The study will investigate the different organisation strategies to get a better understanding of patients' behaviour. The behaviour is assessed with a questionnaire containing 14 questions on the management of medication including single choice, multiple choice and free text questions. As example the number of patients already using a medication organisation system will be assessed, the number of patients using a weekly or daily pillbox will be assessed, and who is filling the medication organisation system.

    Time frame: retrospective 3 months

  2. Insight in patients' comprehension of generics

    Patients have a different comprehension of generics including their advantages and disadvantages. The study will investigate patients' comprehension of generics to get a better understanding of patients' behaviour. The comprehension is assessed with a questionnaire containing 4 questions on the believes about generics including single choice, multiple choice and free text questions. As example the number of patients knowing that they use generics is assessed and the patient's personal opinion on advantages and disadvantages of generics is investigated.

    Time frame: retrospective 3 months

Secondary outcomes

  1. Number of patients using Multicompartment Compliance Aids.

    Assessment of proportion of patients already using Multicompartment Compliance Aids prior to interview.

    Time frame: retrospective 3 months

  2. Number of substitutable medicines.

    Assessment of number of brand name medication which could be substituted by generic medication and willingness of pharmacists to recommend generic medicines.

    Time frame: retrospective 3 months

  3. Swallowing difficulties

    Prevalence of present and/or past swallowing difficulties and coping strategies will be assessed. A specific question (from SWAMECO) on the experienced swallowing difficulties is asked and will be answered on a visual analog scale (0 to 100%). If swallowing-difficulties are present, 2 more questions are asked: Which medication is difficult to swallow and how medication is altered in order to be able to swallow them.

    Time frame: retrospective 3 months

  4. Recommended use of Multicompartment Compliance Aids

    Number of recommended use of Multicompartment Compliance Aids by pharmacists.

    Time frame: retrospective 3 months

07

Study locations

1 site
  • University of Basel
    Basel, Basel-Stadt 4056, Switzerland
08

References and documents

Publications

  • Messerli M, Blozik E, Vriends N, Hersberger KE. Impact of a community pharmacist-led medication review on medicines use in patients on polypharmacy--a prospective randomised controlled trial. BMC Health Serv Res. 2016 Apr 23;16:145. doi: 10.1186/s12913-016-1384-8. PubMed 27108410 ↗
  • Olsson E, Kalvemark Sporrong S. Pharmacists' experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int J Pharm Pract. 2012 Dec;20(6):377-83. doi: 10.1111/j.2042-7174.2012.00214.x. Epub 2012 Jun 1. PubMed 23134096 ↗
  • Hakonsen H, Eilertsen M, Borge H, Toverud EL. Generic substitution: additional challenge for adherence in hypertensive patients? Curr Med Res Opin. 2009 Oct;25(10):2515-21. doi: 10.1185/03007990903192223. PubMed 19708764 ↗
  • Nunney J, Raynor DK, Knapp P, Closs SJ. How do the attitudes and beliefs of older people and healthcare professionals impact on the use of multi-compartment compliance aids?: a qualitative study using grounded theory. Drugs Aging. 2011 May 1;28(5):403-14. doi: 10.2165/11587180-000000000-00000. PubMed 21542662 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Oct 2017, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2017
First posted
Oct 25, 2017
StartActual
Jan 6, 2017
Primary completionActual
Oct 1, 2017
CompletionActual
Oct 24, 2017
Last update
Oct 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03321058
Collaborators
University of Basel
Responsible party
Kurt Hersberger (Prof. Dr., University Hospital, Basel, Switzerland) — Principal investigator
First posted
Oct 25, 2017
Start date
Jan 6, 2017
Primary completion
Oct 1, 2017
Completion
Oct 24, 2017
Last update
Oct 25, 2017

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion